title: Antiresorptive Therapies for the Treatment of Malignant Osteolytic Bone Disease.
abstract: Osteolytic bone disease contributes to morbidity and mortality. Antiresorptive therapies reduce the morbidity of metastatic bone disease and alter the natural progression of malignant bone pathophysiology. Several trials showed improvement in quality of life, delay of skeletal-related events, and improvement in bone pain with these agents. Evolving data suggest a role of improvement in morbidity related to other cancer therapies that have potential side effects. Early indication shows they may alter survival in a subset of patients. This article reviews data confirming the efficacy of antiresorptive agents and discusses preliminary data on preventative therapy.
authors.affiliation: Department of Medicine, Cancer Institute at St. Francis Hospital, The Heart Center, 100 Port Washington Boulevard, Roslyn, NY 11576, USA. Electronic address: bhoomi.mehrotra@chsli.org.
authors.forename: Bhoomi
authors.initials: B
authors.lastname: Mehrotra
mesh_terms: D050071:Bone Density Conservation Agents / Q000009:adverse effects / Q000627:therapeutic use*; D001859:Bone Neoplasms / Q000188:drug therapy* / Q000503:physiopathology; D004164:Diphosphonates / Q000009:adverse effects / Q000627:therapeutic use*; D018450:Disease Progression; D006801:Humans; D010014:Osteolysis / Q000188:drug therapy* / Q000503:physiopathology; D011788:Quality of Life
chemical_list: D050071:Bone Density Conservation Agents; D004164:Diphosphonates
keywords: Antiresorptive therapy; Bisphosphonate; Malignant bone disease; Osteolytic bone disease; Pamidronate; Receptor activator of nuclear factor κB ligand (RANKL) inhibitor (denosumab); Zoledronic acid